At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
|Articles|October 16, 2017
What Are the Key Strategies Necessary to Marketing a Community Pharmacy?
Educating staff is one key step toward implemeting a marketing strategy for a community pharmacy.
Advertisement
In this interview with Pharmacy Times at the 2017 National Community Pharmacists Association Annual Convention (NCPA), Bruce Kneeland, who is a community pharmacist marketing consultant, explains the importance of a marketing program in helping differentiate community pharmacies from their competition.
Advertisement
Related to this article
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
4
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
5